Sequella Presentation at the 45th ICAAC Meeting, Washington, DC

Sequella, Inc. 9610 Medical Center Drive Rockville, MD 20850 Tele: 301-762-7776 www.sequella.com NEWS RELEASE FOR IMMEDIATE RELEASE Sequella Announces Data Presentation at the 45th ICAAC Meeting ROCKVILLE, Md, November 14, 2005-- Sequella, Inc., a privately held biotechnology company developing products for infectious disease, announced today that SQ109 and other pre-clinical data were accepted for presentation at the 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC 45th Annual Meeting is scheduled to take place from December 16 – 19, 2005 at the Washington, DC Convention Center. Dr. Boris Nikonenko is scheduled to present, "Combination Chemotherapy of M. tuberculosis - Infected Mice with SQ109 and First-Line TB Drugs" in the 10:00AM to 11:30AM poster session on Sunday, December 18, 2005. This study demonstrated that the Sequella anti-TB compound called SQ109 improved outcome and shortened therapy duration when substituted for Ethambutol in combination with Isoniazid and Rifampin in the initial phase of TB treatment. Dr. Elena Bogatcheva is scheduled to present, “Identification of New Scaffolds for New Anti-TB Agents” in the 10:00 AM to 11:30 AM poster session on Sunday, December 18, 2005. A diverse library of diamines was synthesized and screened against TB in vitro and in vivo . Piperazine and homopiperazine were identified as promising new scaffolds with anti-TB activity, demonstrating MIC below 5 µg/ml, suitable in vitro cytotoxicity, and good LogP values. Selected compounds from the homopiperazine and piperazine series demonstrated potent activity in mice. This work highlights the need for new and more effective drugs to shorten the standard TB drug regimen and to treat emerging drug resistant infection. About Sequella, Inc. Sequella, Inc. is a clinical stage biotechnology company developing novel infectious disease products. The company’s lead product candidate, the Transdermal Patch for diagnosis of TB disease, is being tested in an international phase III clinical trial, with enrollment completed in six clinical centers. Sequella conducts discovery and pre-clinical research at its Rockville headquarters which houses chemistry and microbiology laboratories, and a BSL-3 facility. For more information, please visit www.sequella.com. Media Contact: Corporate Development Sequella, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 301-762-7776 (phone); 301-762-7778 (fax)

The release as fetched from its publisher. sequella.com ↗